Edition:
United States

Valeant Pharmaceuticals International Inc (VRX)

VRX on New York Consolidated

12.92USD
16 Oct 2017
Change (% chg)

-- (--)
Prev Close
$12.92
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
14,961,362
52-wk High
$24.30
52-wk Low
$8.31

Latest Key Developments (Source: Significant Developments)

Solta Medical receives FDA 510(k) clearance for thermage FLX™ system
Wednesday, 4 Oct 2017 05:16pm EDT 

Oct 4 (Reuters) - Valeant Pharmaceuticals International Inc :Solta medical receives fda 510(k) clearance for thermage flx™ system, newest generation skin smoothing technology.Solta medical - new thermage flx system is expected to be commercially available during last quarter of 2017.  Full Article

Valeant announces pricing of private offering of senior secured notes
Monday, 2 Oct 2017 07:47pm EDT 

Oct 2 (Reuters) - Valeant Pharmaceuticals International Inc :Valeant announces pricing of private offering of senior secured notes.Priced its previously announced offering of $1 billion aggregate principal amount of 5.500% senior secured notes due 2025.  Full Article

Valeant commences cash tender offers for up to $1 bln outstanding principal amount
Monday, 2 Oct 2017 07:36am EDT 

Oct 2 (Reuters) - Valeant Pharmaceuticals International Inc :Valeant and one of its subsidiaries commence cash tender offers for up to $1,000,000,000 outstanding principal amount.Valeant - ‍tender offers will expire at 11:59 p.m., new york city time, on october 30, 2017​.  Full Article

Valeant announces launch of private offering of senior secured notes
Monday, 2 Oct 2017 07:35am EDT 

Oct 2 (Reuters) - Valeant Pharmaceuticals International Inc :Valeant announces launch of private offering of senior secured notes.Valeant - ‍it has launched an offering of $1 billion aggregate principal amount of senior secured notes due 2025​.Valeant - to use proceeds from offering, cash on hand, to repurchase $1 billion of its outstanding 5.375% senior notes due 2020​.Valeant - to also use net proceeds from offering, cash on hand, to repurchase unit's outstanding 7.000% senior notes due 2020.  Full Article

Valeant Pharmaceuticals provides update on Canadian regulatory filing about future financing plans
Wednesday, 27 Sep 2017 09:23pm EDT 

Sept 27 (Reuters) - Valeant :Valeant pharmaceuticals provides update on canadian regulatory filing about future financing plans.Company filed a routine private placement exemption application with autorité des marchés financiers.  Full Article

Ortho Dermatologics submits NDA to U.S. FDA for psoriasis treatment IDP-118
Tuesday, 5 Sep 2017 09:20am EDT 

Sept 5 (Reuters) - Valeant Pharmaceuticals International Inc :Ortho dermatologics submits new drug application to the u.s. Food and drug administration for psoriasis treatment idp-118.Valeant - in both studies IDP-118 met primary efficacy endpoint.Valeant - ‍ortho dermatologics' nda for idp-118​ also includes long-term safety study with patients followed for one year.  Full Article

Valeant director Richard Deschutter reports purchase of 10,000 shares of co's common stock
Tuesday, 22 Aug 2017 05:06pm EDT 

Aug 22 (Reuters) - Valeant Pharmaceuticals International Inc :Valeant director Richard Deschutter reports purchase of 10,000 shares of co's common stock on Aug. 21 - SEC filing.  Full Article

Valeant receives FDA confirmation of inspection for Tampa facility
Wednesday, 16 Aug 2017 04:15pm EDT 

Aug 16 (Reuters) - Valeant Pharmaceuticals International Inc :Valeant receives FDA confirmation of voluntary action indicated (VAI) inspection classification for tampa facility.Valeant - ‍manufacturing uncertainties related to current & upcoming regulatory submissions to be eliminated for products manufactured at tampa facility​.Valeant - ‍FDA confirmed it intends to issue voluntary action indicated inspection classification for bausch + lomb manufacturing facility in tampa.Valeant - received approval Tuesday for a supplemental NDA for tampa​ facility to be a release testing facility for drug substance for Alaway.  Full Article

Paulson & Co dissolves share stake in Pfizer, ups in Valeant ‍​
Monday, 14 Aug 2017 05:12pm EDT 

Aug 14 (Reuters) - Paulson & Co Inc : :Paulson & Co dissolves share stake in Pfizer- SEC filing ‍​.Paulson & Co Inc raises share stake in Valeant Pharmaceuticals by 12.5 percent to 21.8 million shares ‍​.‍Paulson & Co - Change in holdings are as of June 30, 2017 and compared with the previous quarter ended as of March 31, 2017 ​.  Full Article

Paulson & Co reports 6 pct stake in Valeant, as of Aug 9
Wednesday, 9 Aug 2017 05:36pm EDT 

Aug 9 (Reuters) - Paulson & Co Inc::Paulson & Co Inc reports 6 percent stake in Valeant as of Aug 9 - SEC filing.Paulson & Co had earlier reported a stake of 6.3 percent in Valeant as of June 14‍​.  Full Article

BRIEF-Ortho Dermatologics, unit of Valeant, announces two-year findings from pivotal phase 3 study of Siliq injection data demonstrating long-term efficacy profile

* Ortho Dermatologics announces two-year findings from pivotal phase 3 study of Siliq™ (brodalumab) injection data demonstrating long-term efficacy profile